<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197054</url>
  </required_header>
  <id_info>
    <org_study_id>A-12227</org_study_id>
    <secondary_id>IND 11220</secondary_id>
    <nct_id>NCT00197054</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.</brief_title>
  <official_title>A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30%&#xD;
      efficacy against clinical episodes of malaria and approximately 58% efficacy against severe&#xD;
      malaria disease. As a potential improvement to RTS,S/AS02A, another candidate vaccine&#xD;
      RTS,S/AS01B is being developed in parallel in collaboration with the Walter Reed Army&#xD;
      Institute of Research (WRAIR). This study will be the first administration of the RTS,S/AS01B&#xD;
      vaccine to the African adults to establish safety and immunogenicity in this population.&#xD;
      Preliminary indication of vaccine efficacy with this adjuvant will be established by&#xD;
      monitoring the time to the first infection with Plasmodium falciparum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises of 3 groups and the participating subjects will be randomly allocated to&#xD;
      one of the three groups. The first group will receive RTS,S/AS01B, the second group will&#xD;
      receive RTS,S/AS02A and the third group will receive rabies vaccine. Immunization will be&#xD;
      given by IM injection on 0, 1, 2 month schedule. Infants will be followed up daily for 7 days&#xD;
      for solicited symptoms and 30 days for unsolicited symptoms after each vaccine dose. Serious&#xD;
      adverse events will be recorded throughout the study period. A week prior to Dose 3, subjects&#xD;
      will be treated with a licenced anti-malarial drug. Starting from two weeks after Dose 3, the&#xD;
      subjects will be monitored for a 14-week duration for detection of malaria infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Proportion of Subjects With Grade 3 Solicited and Unsolicited General Reactions After Vaccination of RTS, S/AS02A and RTS, S/AS01B</measure>
    <time_frame>7 day follow-up (day of vaccination + 6 days)</time_frame>
    <description>Proportion of subjects with grade 3 solicited and unsolicited general reactions after vaccination of RTS, S/AS02A and RTS, S/AS01B during a 7 day follow-up period (day of vaccination + 6 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Administered Doses Eliciting Grade 3 Unsolicited Symptoms</measure>
    <time_frame>6.5 months</time_frame>
    <description>Grade 3 unsolicited symptoms reported following any number of administered doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Doses Eliciting Solicited Local Symptoms Reported Over 7 Day Follow-up Period</measure>
    <time_frame>7 day follow-up period (day of vaccination + 6 days)</time_frame>
    <description>Incidence overall solicited general and local reactions over 7 day follow-up period after dose 1, 2 and 3 (Total Cohort)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Occurrence of SAEs</measure>
    <time_frame>months 6.5 thru 12</time_frame>
    <description>Percentage of subjects experiencing SAEs classified by MedRA System Organ Class and Preferred Term (Month 6.5-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Occurrence of SAEs</measure>
    <time_frame>months 0 thru 12</time_frame>
    <description>Percentage of subjects reporting SAEs classified by MedDRA System Organ Class and Preferred Term (Month 0-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Hematology Parameters Below Normal Range</measure>
    <time_frame>Days 0, 6, 66, and 90; Months 6 and 12</time_frame>
    <description>Occurrence of hematology parameters below normal range (Total Cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Biochemistry Parameters Above Normal Ranges</measure>
    <time_frame>Days 0, 6, and 90</time_frame>
    <description>Occurrence of parameters of biochemical monitoring above normal ranges (Total Cohort)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected &gt;10 mIU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(D90)</measure>
    <time_frame>Day 90</time_frame>
    <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(M12)</measure>
    <time_frame>Month 12</time_frame>
    <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PRE=Prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(D90)</measure>
    <time_frame>Day 90</time_frame>
    <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(M12)</measure>
    <time_frame>Month 12</time_frame>
    <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PRE=Prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (D90)</measure>
    <time_frame>Day 90</time_frame>
    <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (M12)</measure>
    <time_frame>Month 12</time_frame>
    <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Geometric mean antibody titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PRE=Prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (D90)</measure>
    <time_frame>Day 90</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (M12)</measure>
    <time_frame>Month 12</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (D90)</measure>
    <time_frame>Day 90</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (M12)</measure>
    <time_frame>Month 12</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PRE= prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PII (D60)</measure>
    <time_frame>1 month post dose 2</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PII(D60)= post dose 2 (day 60)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (D90)</measure>
    <time_frame>1 month post dose 3</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M6.5)</measure>
    <time_frame>4 months post dose 3</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M6.5)= post dose 3 (month 6.5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M12)</measure>
    <time_frame>10 months post dose 3</time_frame>
    <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M12)= post dose 3 (month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PRE</measure>
    <time_frame>PRE</time_frame>
    <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PII (D60)</measure>
    <time_frame>post dose 2 (day 60)</time_frame>
    <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (D90)</measure>
    <time_frame>post dose 3 (day 90)</time_frame>
    <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (M6.5)</measure>
    <time_frame>post dose 3 (month 6.5)</time_frame>
    <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PRE= prevaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PII (D60)</measure>
    <time_frame>1 month post dose 2</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3.&#xD;
PII(D60)= post dose 2 (day 60)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (D90)</measure>
    <time_frame>1 month post dose 3</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M6.5)</measure>
    <time_frame>4 months post dose 3</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M6.5)= post dose 3 (month 6.5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M12)</measure>
    <time_frame>10 months post dose 3</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M12)= post dose 3 (month 12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Infection Status PRE</measure>
    <time_frame>Prevaccination</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Infection Status PII (D60)</measure>
    <time_frame>post dose 2 (day 60)</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (D90)</measure>
    <time_frame>post dose 3 (day 90)</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (M6.5)</measure>
    <time_frame>post dose 3 (month 6.5)</time_frame>
    <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy: Vaccine Efficacy Against P. Falciparum Infection</measure>
    <time_frame>14 days after dose 3 and extending for 14 weeks</time_frame>
    <description>Number of subjects with an episode of parasitemia (first recording of infection of asexual stage falciparum parasites &gt;0 detected by active detection of infection (ADI) or passive case detection)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Positive and Negative Parasite Density</measure>
    <time_frame>at month 6.5</time_frame>
    <description>Percentage of participants with positive and negative parasite density at month 6.5</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) of Asexual P. Falciparum Parasitemia</measure>
    <time_frame>Month 6.5</time_frame>
    <description>Geometric Mean Antibody Titers (GMTs) of Asexual P. falciparum parasitemia at Month 6.5</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Plasmodium Falciparum</condition>
  <arm_group>
    <arm_group_label>VACC 1 (RTS, S/AS01B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VACC 2 (RTS, S/AS02A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabipur (Rabies) Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RTS, S/AS01B</intervention_name>
    <description>0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
    <arm_group_label>VACC 1 (RTS, S/AS01B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RTS, S/AS02A</intervention_name>
    <description>0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
    <arm_group_label>VACC 2 (RTS, S/AS02A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabipur (Rabies) Vaccine</intervention_name>
    <description>1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
    <arm_group_label>Rabipur (Rabies) Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male or female volunteers aged between 18 and 35 years at the time of first&#xD;
             vaccination who have given written consent for their participation in the study were&#xD;
             included&#xD;
&#xD;
          -  If the volunteer is female, she must be of non-childbearing potential, i.e. either&#xD;
             surgically sterilized or one year post-menopausal; or, if of childbearing potential,&#xD;
             she must be abstinent or have used adequate contraceptive precautions for 30 days&#xD;
             prior to vaccination, have a negative pregnancy test and must agree to continue such&#xD;
             precautions for two months after completion of the vaccination series&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  If a subject plans to take vaccine not foreseen by the study protocol within 30 days&#xD;
             of the first dose of vaccine(s) with the exception of tetanus toxoid will be excluded&#xD;
&#xD;
          -  Volunteers with any confirmed or suspected immunosuppressive or immunodeficient&#xD;
             conditions&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency&#xD;
&#xD;
          -  History of allergic reactions to previous immunizations&#xD;
&#xD;
          -  HBsAg positive subjects&#xD;
&#xD;
          -  History of splenectomy&#xD;
&#xD;
          -  Pregnant or lactating females will be excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.S. Army Research Unit-Kenya</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>GSK and WRAIR</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>255 subjects were enrolled and randomized 1:1:1 into each arm at Kombewa Clinic, US Army Medical Research Unit, Kisumu Kenya.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RTS, S/AS02A</title>
          <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="P2">
          <title>RTS, S/AS01B</title>
          <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="P3">
          <title>Rabipur (Rabies) Vaccine</title>
          <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved from area</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RTS, S/AS02A</title>
          <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="B2">
          <title>RTS, S/AS01B</title>
          <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="B3">
          <title>Rabipur (Rabies) Vaccine</title>
          <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="5.16"/>
                    <measurement group_id="B2" value="24.9" spread="5.50"/>
                    <measurement group_id="B3" value="26.1" spread="5.10"/>
                    <measurement group_id="B4" value="25.4" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Proportion of Subjects With Grade 3 Solicited and Unsolicited General Reactions After Vaccination of RTS, S/AS02A and RTS, S/AS01B</title>
        <description>Proportion of subjects with grade 3 solicited and unsolicited general reactions after vaccination of RTS, S/AS02A and RTS, S/AS01B during a 7 day follow-up period (day of vaccination + 6 days).</description>
        <time_frame>7 day follow-up (day of vaccination + 6 days)</time_frame>
        <population>Rabipur was a comparator vaccine and not relevant to results of this primary outcome. Results for Rabipur were not presented in data table.</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Proportion of Subjects With Grade 3 Solicited and Unsolicited General Reactions After Vaccination of RTS, S/AS02A and RTS, S/AS01B</title>
          <description>Proportion of subjects with grade 3 solicited and unsolicited general reactions after vaccination of RTS, S/AS02A and RTS, S/AS01B during a 7 day follow-up period (day of vaccination + 6 days).</description>
          <population>Rabipur was a comparator vaccine and not relevant to results of this primary outcome. Results for Rabipur were not presented in data table.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Number of Administered Doses Eliciting Grade 3 Unsolicited Symptoms</title>
        <description>Grade 3 unsolicited symptoms reported following any number of administered doses</description>
        <time_frame>6.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Administered Doses Eliciting Grade 3 Unsolicited Symptoms</title>
          <description>Grade 3 unsolicited symptoms reported following any number of administered doses</description>
          <units>administered doses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Doses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Doses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.3" upper_limit="3.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="1" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="1" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Number of Doses Eliciting Solicited Local Symptoms Reported Over 7 Day Follow-up Period</title>
        <description>Incidence overall solicited general and local reactions over 7 day follow-up period after dose 1, 2 and 3 (Total Cohort)</description>
        <time_frame>7 day follow-up period (day of vaccination + 6 days)</time_frame>
        <population>number of administered doses</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Doses Eliciting Solicited Local Symptoms Reported Over 7 Day Follow-up Period</title>
          <description>Incidence overall solicited general and local reactions over 7 day follow-up period after dose 1, 2 and 3 (Total Cohort)</description>
          <population>number of administered doses</population>
          <units>Doses</units>
          <param>Number</param>
          <units_analyzed>Doses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Doses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Axillary)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Occurrence of SAEs</title>
        <description>Percentage of subjects experiencing SAEs classified by MedRA System Organ Class and Preferred Term (Month 6.5-12)</description>
        <time_frame>months 6.5 thru 12</time_frame>
        <population>Number of subjects with at least one administered dose</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Occurrence of SAEs</title>
          <description>Percentage of subjects experiencing SAEs classified by MedRA System Organ Class and Preferred Term (Month 6.5-12)</description>
          <population>Number of subjects with at least one administered dose</population>
          <units>% of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericardial Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound Necrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abscess Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lobar Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Tuberculosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trichomoniasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Occurrence of SAEs</title>
        <description>Percentage of subjects reporting SAEs classified by MedDRA System Organ Class and Preferred Term (Month 0-12)</description>
        <time_frame>months 0 thru 12</time_frame>
        <population>Number of subjects with at least one administered dose</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Occurrence of SAEs</title>
          <description>Percentage of subjects reporting SAEs classified by MedDRA System Organ Class and Preferred Term (Month 0-12)</description>
          <population>Number of subjects with at least one administered dose</population>
          <units>% of subjects reporting symptom</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericardial Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peptic Ulcer Haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound Necrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abscess Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disseminated Tuberculosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.3" upper_limit="8.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="3.5" lower_limit="0.7" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lobar Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Cryptococcal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumocystis Jiroveci Pheumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Tuberculosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trichomoniasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Encephalitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Hematology Parameters Below Normal Range</title>
        <description>Occurrence of hematology parameters below normal range (Total Cohort)</description>
        <time_frame>Days 0, 6, 66, and 90; Months 6 and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Hematology Parameters Below Normal Range</title>
          <description>Occurrence of hematology parameters below normal range (Total Cohort)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: Day 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hemoglobin: Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Day 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC: Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Biochemistry Parameters Above Normal Ranges</title>
        <description>Occurrence of parameters of biochemical monitoring above normal ranges (Total Cohort)</description>
        <time_frame>Days 0, 6, and 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Biochemistry Parameters Above Normal Ranges</title>
          <description>Occurrence of parameters of biochemical monitoring above normal ranges (Total Cohort)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin: Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT: Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PRE</title>
        <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected &gt;10 mIU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>&gt;=3.3 MIU/ML</title>
            <description>Seropositive: &gt;3.3 mlU/mL</description>
          </group>
          <group group_id="O2">
            <title>&gt;=10 MIU/ML</title>
            <description>Seroprotected: &gt;10 mlU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PRE</title>
          <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected &gt;10 mIU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Non-infected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="27.1" upper_limit="51.5"/>
                    <measurement group_id="O2" value="37.3" lower_limit="25.8" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Infected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="39.6" upper_limit="60.4"/>
                    <measurement group_id="O2" value="44.8" lower_limit="34.6" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(D90)</title>
        <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>Day 90</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>&gt;=3.3 MIU/ML</title>
            <description>Seropositive: &gt;3.3 mlU/mL</description>
          </group>
          <group group_id="O2">
            <title>&gt;=10 MIU/ML</title>
            <description>Seroprotected: &gt;10 mlU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(D90)</title>
          <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Non-infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="87.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="93.0" lower_limit="83.0" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="86.8" upper_limit="97.6"/>
                    <measurement group_id="O2" value="91.6" lower_limit="84.1" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(M12)</title>
        <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
        <time_frame>Month 12</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>&gt;=3.3 MIU/ML</title>
            <description>Seropositive: &gt;3.3 mlU/mL</description>
          </group>
          <group group_id="O2">
            <title>&gt;=10 MIU/ML</title>
            <description>Seroprotected: &gt;10 mlU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Infection Status PIII(M12)</title>
          <description>Seropositivity rates and GMTs for Anti-HBs antibodies by infection status (Total Cohort) Seropositive &gt;3.3 mlU/mL; Seroprotected: &gt;10 mlU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Non-infected: PIII(M12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="88.7" upper_limit="99.9"/>
                    <measurement group_id="O2" value="91.5" lower_limit="79.6" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Infected: PIII(M12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="85.3" upper_limit="97.4"/>
                    <measurement group_id="O2" value="90.6" lower_limit="82.3" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PRE</title>
        <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PRE=Prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>Subject with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PRE</title>
          <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PRE=Prevaccination</description>
          <population>Subject with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(D90)</title>
        <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
        <time_frame>Day 90</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(D90)</title>
          <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
          <population>Subjects with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(M12)</title>
        <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
        <time_frame>Month 12</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-HBs Antibodies by Vaccine Group PIII(M12)</title>
          <description>Seropositivity rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seropositive &gt;3.3 mlU/ML&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
          <population>Subjects with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PRE</title>
        <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PRE=Prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PRE</title>
          <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PRE=Prevaccination</description>
          <population>Subjects with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (D90)</title>
        <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
        <time_frame>Day 90</time_frame>
        <population>Subject with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (D90)</title>
          <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
          <population>Subject with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (M12)</title>
        <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
        <time_frame>Month 12</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rates for Anti-HBs Antibodies by Vaccine Group PIII (M12)</title>
          <description>Seroprotection rates for Anti-HBs antibodies by vaccine group (ATP Cohort for Immunogenicity).&#xD;
Seroprotected &gt;10 mlU/mL&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
          <population>Subjects with available results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PRE</title>
        <description>Geometric mean antibody titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PRE=Prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PRE</title>
          <description>Geometric mean antibody titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PRE=Prevaccination</description>
          <population>Subjects with available results</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="6.0" upper_limit="20.4"/>
                    <measurement group_id="O2" value="18.3" lower_limit="9.4" upper_limit="35.3"/>
                    <measurement group_id="O3" value="23.6" lower_limit="11.3" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (D90)</title>
        <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
        <time_frame>Day 90</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (D90)</title>
          <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(D90)= post dose 3 (Day 90)</description>
          <population>Subjects with available results</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1434.9" lower_limit="743.0" upper_limit="2770.9"/>
                    <measurement group_id="O2" value="1714.3" lower_limit="836.1" upper_limit="3515.0"/>
                    <measurement group_id="O3" value="31.7" lower_limit="14.6" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (M12)</title>
        <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
        <time_frame>Month 12</time_frame>
        <population>Subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Vaccine Group PIII (M12)</title>
          <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by vaccine group (According to protocol (ATP) Cohort for Immunogenicity)&#xD;
PIII(M12)= post dose 3 (Month 12)</description>
          <population>Subjects with available results</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593.7" lower_limit="317.0" upper_limit="1111.9"/>
                    <measurement group_id="O2" value="635.8" lower_limit="341.9" upper_limit="1182.5"/>
                    <measurement group_id="O3" value="28.6" lower_limit="13.8" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PRE</title>
        <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody</title>
            <description>Geometric Mean Antibody titer calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PRE</title>
          <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Prevaccination</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="5.7" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="7.9" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (D90)</title>
        <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>Day 90</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody</title>
            <description>Geometric Mean Antibody titer calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (D90)</title>
          <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1558.3" lower_limit="744.7" upper_limit="3260.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1532.6" lower_limit="844.2" upper_limit="2782.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (M12)</title>
        <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
        <time_frame>Month 12</time_frame>
        <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody</title>
            <description>Geometric Mean Antibody titer calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HBs Antibodies by Infection Status PIII (M12)</title>
          <description>Geometric mean titers (GMTs) for Anti-HBs antibodies by infection status (Total Cohort) Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M12)= post dose 3 (month 12)</description>
          <population>The Total Vaccinated Cohort includes all vaccinated subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-infected: PIII(M12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765.8" lower_limit="384.8" upper_limit="1524.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infected: PIII(M12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499.0" lower_limit="293.1" upper_limit="849.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PRE</title>
        <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PRE= prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PRE</title>
          <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PRE= prevaccination</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.6" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.9" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.4" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PII (D60)</title>
        <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PII(D60)= post dose 2 (day 60)</description>
        <time_frame>1 month post dose 2</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PII (D60)</title>
          <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PII(D60)= post dose 2 (day 60)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="23.9" upper_limit="41.6"/>
                    <measurement group_id="O2" value="16.7" lower_limit="12.9" upper_limit="21.7"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (D90)</title>
        <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>1 month post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 213 subjects (72 RTS,S/AS01B, 72 RTS,S/AS02A, 69 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (D90)</title>
          <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(D90)= post dose 3 (day 90)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 213 subjects (72 RTS,S/AS01B, 72 RTS,S/AS02A, 69 rabies vaccine)</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="31.7" upper_limit="54.2"/>
                    <measurement group_id="O2" value="21.4" lower_limit="16.0" upper_limit="28.7"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M6.5)</title>
        <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M6.5)= post dose 3 (month 6.5)</description>
        <time_frame>4 months post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 207 subjects (69 RTS,S/AS01B, 69 RTS,S/AS02A, 69 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M6.5)</title>
          <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M6.5)= post dose 3 (month 6.5)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 207 subjects (69 RTS,S/AS01B, 69 RTS,S/AS02A, 69 rabies vaccine)</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="17.1" upper_limit="31.1"/>
                    <measurement group_id="O2" value="13.1" lower_limit="9.7" upper_limit="17.7"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M12)</title>
        <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M12)= post dose 3 (month 12)</description>
        <time_frame>10 months post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 189 subjects (61 RTS,S/AS01B, 62 RTS,S/AS02A, 66 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-CS Antibodies up to Month 12 by Vaccine Group PIII (M12)</title>
          <description>Geometric mean titers (GMTs) for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3 PIII(M12)= post dose 3 (month 12)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 189 subjects (61 RTS,S/AS01B, 62 RTS,S/AS02A, 66 rabies vaccine)</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="10.7" upper_limit="18.9"/>
                    <measurement group_id="O2" value="7.3" lower_limit="5.2" upper_limit="10.2"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.3" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PRE</title>
        <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
        <time_frame>PRE</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody Titer</title>
            <description>GMTs calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PRE</title>
          <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.9" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PII (D60)</title>
        <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
        <time_frame>post dose 2 (day 60)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody Titer</title>
            <description>GMTs calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PII (D60)</title>
          <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infected: PII(D60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.4" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infected: PII(D60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" lower_limit="28.1" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (D90)</title>
        <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>post dose 3 (day 90)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody Titer</title>
            <description>GMTs calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (D90)</title>
          <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="12.7" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="32.6" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (M6.5)</title>
        <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
        <time_frame>post dose 3 (month 6.5)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Antibody Titer</title>
            <description>GMTs calculated on all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Anti-CS Antibodies by Infection Status PIII (M6.5)</title>
          <description>Geometric mean antibody titers (GMTs) for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For GMTs by infection status arms have been combined.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infected: PIII(M6.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.7" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infected: PIII(M6.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="20.3" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PRE</title>
        <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PRE= prevaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>Immunogenicity (ATP Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PRE</title>
          <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PRE= prevaccination</description>
          <population>Immunogenicity (ATP Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="76.8" upper_limit="93.4"/>
                    <measurement group_id="O2" value="75.7" lower_limit="64.3" upper_limit="84.9"/>
                    <measurement group_id="O3" value="84.9" lower_limit="74.6" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PII (D60)</title>
        <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3.&#xD;
PII(D60)= post dose 2 (day 60)</description>
        <time_frame>1 month post dose 2</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PII (D60)</title>
          <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3.&#xD;
PII(D60)= post dose 2 (day 60)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 222 subjects (75 RTS,S/AS01B, 74 RTS,S/AS02A, 73 rabies vaccine)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="92.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O3" value="84.9" lower_limit="74.6" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (D90)</title>
        <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>1 month post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 213 subjects (72 RTS,S/AS01B, 72 RTS,S/AS02A, 69 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (D90)</title>
          <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(D90)= post dose 3 (day 90)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 213 subjects (72 RTS,S/AS01B, 72 RTS,S/AS02A, 69 rabies vaccine)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="92.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.0" upper_limit="100"/>
                    <measurement group_id="O3" value="82.6" lower_limit="71.6" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M6.5)</title>
        <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M6.5)= post dose 3 (month 6.5)</description>
        <time_frame>4 months post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 207 subjects (69 RTS,S/AS01B, 69 RTS,S/AS02A, 69 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M6.5)</title>
          <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M6.5)= post dose 3 (month 6.5)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 207 subjects (69 RTS,S/AS01B, 69 RTS,S/AS02A, 69 rabies vaccine)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="92.2" upper_limit="100"/>
                    <measurement group_id="O2" value="98.6" lower_limit="92.2" upper_limit="100"/>
                    <measurement group_id="O3" value="79.7" lower_limit="68.3" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M12)</title>
        <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M12)= post dose 3 (month 12)</description>
        <time_frame>10 months post dose 3</time_frame>
        <population>Immunogenicity (According to protocol (ATP) Cohort): 189 subjects (61 RTS,S/AS01B, 62 RTS,S/AS02A, 66 rabies vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Vaccine Group PIII (M12)</title>
          <description>Seropositivity rates for Anti-CS antibodies accessed prevaccination, 1 month post dose 2, 1 month post dose 3, 4 months post dose 3 and 10 months post dose 3&#xD;
PIII(M12)= post dose 3 (month 12)</description>
          <population>Immunogenicity (According to protocol (ATP) Cohort): 189 subjects (61 RTS,S/AS01B, 62 RTS,S/AS02A, 66 rabies vaccine)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.1" upper_limit="100"/>
                    <measurement group_id="O2" value="95.2" lower_limit="86.5" upper_limit="99.0"/>
                    <measurement group_id="O3" value="80.3" lower_limit="68.7" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PRE</title>
        <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
        <time_frame>Prevaccination</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Seropositive</title>
            <description>Seropositive: &gt;0.5 EU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PRE</title>
          <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PRE= Pre-vaccination</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" lower_limit="63.6" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Non-infected: PRE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" lower_limit="74.6" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PII (D60)</title>
        <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
        <time_frame>post dose 2 (day 60)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Seropositive</title>
            <description>Seropositive: &gt;0.5 EU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PII (D60)</title>
          <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PII(D60)= post dose 2 (day 60)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Infected: PII(D60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Non-infected: PII(D60)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (D90)</title>
        <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
        <time_frame>post dose 3 (day 90)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Seropositive</title>
            <description>Seropositive: &gt;0.5 EU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (D90)</title>
          <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(D90)= post dose 3 (day 90)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Non-infected: PIII(D90)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (M6.5)</title>
        <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
        <time_frame>post dose 3 (month 6.5)</time_frame>
        <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Seropositive</title>
            <description>Seropositive: &gt;0.5 EU/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositivity Rates for Anti-CS Antibodies by Infection Status PIII (M6.5)</title>
          <description>Seropositivity rates for Anti-CS antibodies by infection status on RTS,S/AS01B and RTS,S/AS02A recipients only Seropositive: &gt;0.5EU/mL Infection defined as P. falciparum asexual parasitemia &gt;0 PIII(M6.5)= post dose 3 (month 6.5)</description>
          <population>The ATP Cohort includes all evaluable subjects for whom data were available. For seropositivity rates by infection status arms have been combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Infected: PIII(M6.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="90.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Non-infected: PIII(M6.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="93.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Efficacy: Vaccine Efficacy Against P. Falciparum Infection</title>
        <description>Number of subjects with an episode of parasitemia (first recording of infection of asexual stage falciparum parasites &gt;0 detected by active detection of infection (ADI) or passive case detection)</description>
        <time_frame>14 days after dose 3 and extending for 14 weeks</time_frame>
        <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Vaccine Efficacy Against P. Falciparum Infection</title>
          <description>Number of subjects with an episode of parasitemia (first recording of infection of asexual stage falciparum parasites &gt;0 detected by active detection of infection (ADI) or passive case detection)</description>
          <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Positive and Negative Parasite Density</title>
        <description>Percentage of participants with positive and negative parasite density at month 6.5</description>
        <time_frame>at month 6.5</time_frame>
        <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine). Missing subject data: S/AS01B = 4, S/AS02A = 6, Rabipur = 4</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive and Negative Parasite Density</title>
          <description>Percentage of participants with positive and negative parasite density at month 6.5</description>
          <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine). Missing subject data: S/AS01B = 4, S/AS02A = 6, Rabipur = 4</population>
          <units>% of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parasite Density: % of Negative Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="93.2"/>
                    <measurement group_id="O3" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parasite Density: % of Positive Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titers (GMTs) of Asexual P. Falciparum Parasitemia</title>
        <description>Geometric Mean Antibody Titers (GMTs) of Asexual P. falciparum parasitemia at Month 6.5</description>
        <time_frame>Month 6.5</time_frame>
        <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>RTS, S/AS01B</title>
            <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
          <group group_id="O2">
            <title>RTS, S/AS02A</title>
            <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
          <group group_id="O3">
            <title>Rabipur (Rabies) Vaccine</title>
            <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) of Asexual P. Falciparum Parasitemia</title>
          <description>Geometric Mean Antibody Titers (GMTs) of Asexual P. falciparum parasitemia at Month 6.5</description>
          <population>Efficacy (According to protocol (ATP) Cohort): 228 subjects (74 RTS,S/AS01B, 79 RTS,S/AS02A, 75 rabies vaccine).</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1122" lower_limit="-525.0" upper_limit="2769.0"/>
                    <measurement group_id="O2" value="342" lower_limit="-115.4" upper_limit="799.8"/>
                    <measurement group_id="O3" value="711" lower_limit="-846.8" upper_limit="2268.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>(RTS, S/AS01B)</title>
          <description>RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.&#xD;
RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="E2">
          <title>(RTS, S/AS02A)</title>
          <description>RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.&#xD;
RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.</description>
        </group>
        <group group_id="E3">
          <title>Rabipur (Rabies) Vaccine</title>
          <description>Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months&#xD;
Rabipur (Rabies) Vaccine: .0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="85"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="85"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bowel sounds</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lip exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="85"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="85"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pitting oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gonorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hookworm infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Schistosomiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Septic rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Strongyloidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="85"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="85"/>
                <counts group_id="E3" events="48" subjects_affected="48" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="85"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mean cell volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="85"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="85"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="85"/>
                <counts group_id="E2" events="57" subjects_affected="57" subjects_at_risk="85"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="85"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="85"/>
                <counts group_id="E3" events="37" subjects_affected="37" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Mammory duct ectasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough epistaxis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Epixtaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rash pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>LTC Mark Polhemus MD, MC</name_or_title>
      <organization>Kombewa Clinic, US Army Medical Research Unit, Kisumo Kenya</organization>
      <phone>877-379-3788</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

